Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216354 · ClinicalTrials.gov registry record · Phase 1
Fruquintinib Renal Impairment Study
A Phase 1 study of Renal Impairment, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05216354 is a Phase 1 study of Renal Impairment that has completed, run by Hutchmed. The registered enrollment target is 24 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (29% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05216354, a Phase 1 study of Renal Impairment, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
A multicenter, open label, single-dose, single-period, sequential study to assess the effect of renal impairment on the pharmacokinetics of Fruquintinib
Conditions Studied
Interventions
- DRUG Fruquintinib
Study Locations (2)
Florida
- Clinical Pharmacology of Miami - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2023-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05216354
The ClinicalTrials.gov registry entry for NCT05216354 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (29% lower). The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Fruquintinib is the first listed.
NCT05216354 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05216354 about?
NCT05216354 is a clinical study titled "Fruquintinib Renal Impairment Study". A multicenter, open label, single-dose, single-period, sequential study to assess the effect of renal impairment on the pharmacokinetics of Fruquintinib
What is the current status of trial NCT05216354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-03-11. Estimated completion is 2023-06-26.
What conditions does trial NCT05216354 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT05216354?
The interventions under investigation include: Fruquintinib (DRUG).
Who is sponsoring clinical trial NCT05216354?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05216354 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.